Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.
Protara Therapeutics, Inc. (Nasdaq: TARA) is a clinical-stage biotechnology company developing therapies for cancer and rare diseases, and its news flow reflects progress across its investigational programs. Company announcements frequently highlight updates on TARA-002, an investigational cell-based therapy in development for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs), as well as on IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients on long-term parenteral support.
Investors following TARA news can expect detailed coverage of clinical trial milestones, including interim data from the Phase 2 ADVANCED-2 trial in NMIBC and the Phase 2 STARBORN-1 trial in pediatric LMs. Recent press releases have discussed complete response rates, safety and tolerability findings, and regulatory feedback from the U.S. Food and Drug Administration (FDA) on potential registrational paths for TARA-002 in both BCG-unresponsive and BCG-naïve NMIBC populations.
News items also report on regulatory designations and programs, such as Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations for TARA-002 in LMs, and Fast Track and Orphan Drug Designations for IV Choline Chloride in patients on long-term parenteral nutrition. In addition, Protara’s releases describe participation of TARA-002 in the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program.
Another key theme in TARA news is capital markets activity, including underwritten public offerings of common stock under the company’s shelf registration statement on Form S-3, with proceeds directed toward the clinical development of TARA-002 and other programs. Corporate updates may reference conference presentations, such as appearances at healthcare conferences, and scheduled webcasts to review new clinical data.
By monitoring this news page, readers can follow Protara’s disclosed clinical data updates, regulatory interactions, financing events, and other material developments that the company reports through press releases and related communications.
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on cancer and rare disease therapies, has granted inducement equity awards to two new employees. The compensation package includes 14,800 stock options at an exercise price of $3.06 per share and 7,400 RSUs.
The stock options will vest over four years with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years with one-third vesting annually. These grants were approved under Nasdaq Listing Rule 5635(c)(4) as material inducements for employment.
["New talent acquisition with equity-based compensation alignment", "Structured vesting schedule promotes employee retention"]Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on cancer and rare disease therapies, has announced inducement grants to two new employees. The company's Compensation Committee approved 29,500 stock options at an exercise price of $2.80 per share and 14,750 restricted stock units (RSUs) as of July 1, 2025.
The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest over three years, with one-third vesting annually. Both grants are contingent on continued employment with Protara.
Catalio Capital Management has successfully closed its fourth venture fund, Catalio Nexus Fund IV, raising over $400 million in commitments. The fund, which has already made 16 investments, received significant backing from existing and new global institutional investors, RIAs, foundations, and endowments.
The firm, which manages $2 billion in assets across private equity, private credit, and public equities strategies, focuses on investing in breakthrough biomedical technology companies founded by serial scientist-entrepreneurs. Notable investments from Fund IV include co-leading PinkDx's $40 million Series A round, participating in Imperative Care's $150M Series E financing, and Alentis Therapeutics' $180M Series D round.
Fund IV has also invested in Protara Therapeutics (NASDAQ:TARA) through a PIPE transaction and launched two new companies focused on immunology and inflammation: Rhapsogen and TBD Pharma, co-founded by Catalio Venture Partners from Rockefeller University and Johns Hopkins University respectively.
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on cancer and rare disease treatments, has been added to the Russell 3000® Index effective June 30, 2025. The company's pipeline includes clinical trials for TARA-002 in non-muscle invasive bladder cancer and lymphatic malformations, as well as an IV Choline Chloride program for patients on parenteral support.
The Russell 3000® Index, which captures the 4,000 largest U.S. stocks by market capitalization, is widely used by investment managers and institutional investors, with approximately $10.6 trillion in assets benchmarked against Russell US Indexes as of June 2024.
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing cancer and rare disease therapies, has announced its participation in two upcoming investor conferences. The company will participate in a fireside chat at the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference on May 20, 2025, at 12:30 pm ET in New York. Additionally, management will join the TD Cowen 6th Annual Oncology Innovation Summit for a virtual fireside chat on May 27, 2025, at 1:30 pm ET. Both events will be webcast live and temporarily archived on the company's investor relations website.
Protara Therapeutics (TARA) announced inducement grants of stock options and restricted stock units (RSUs) to six new employees. The company's new VP and Chief People Officer, Shane Williams, received 41,000 stock options at $4.32 per share and 20,500 RSUs on April 25, 2025. Additionally, five other new employees were granted a total of 59,100 stock options at $3.46 per share and 29,550 RSUs.
The stock options vest over four years (25% after one year, then 1/36th monthly), while RSUs vest over three years (33 1/3% annually). All grants were approved under the company's 2020 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).
Protara Therapeutics (TARA) announced positive interim results from its Phase 2 ADVANCED-2 trial of TARA-002 for Non-Muscle Invasive Bladder Cancer (NMIBC). The trial showed impressive efficacy in both patient cohorts:
In the BCG-Unresponsive cohort (5 patients):
- 100% complete response rate at any time
- 100% at 6 months
- 80% at 9 months
- 67% at 12 months
In the BCG-Naïve cohort (21 patients):
- 76% complete response rate at any time
- 63% at 6 months
- 63% at 9 months
- 43% at 12 months
The treatment demonstrated a favorable safety profile with no Grade 3 or greater treatment-related adverse events. The company expects to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by end of 2025.
Protara Therapeutics (Nasdaq: TARA) has announced a conference call and webcast scheduled for April 28, 2025, at 8:30 a.m. ET to discuss interim data from their Phase 2 ADVANCED-2 trial. The presentation will focus on updated safety and efficacy data of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC), specifically including data from patients who have reached the 12-month evaluation timepoint.
The data will also be presented during an interactive poster session at the American Urological Association 2025 Annual Meeting on April 26, 2025, at 7:00 a.m. PT. Interested participants can register for the conference call to receive dial-in information, and a live webcast will be available on the company's website.
FAQ
What is the current stock price of Protara Therapeutics (TARA)?
What is the market cap of Protara Therapeutics (TARA)?
